Holen Sie sich die Stockscreener-App
12.48
1.51%
-0.1196
Schlusskurs vom Vortag:
$12.60
Offen:
$12.52
24-Stunden-Volumen:
66,838
Relative Volume:
0.04
Marktkapitalisierung:
$954.57M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-54.42M
KGV:
-12.76
EPS:
-0.9778
Netto-Cashflow:
$-48.99M
1W Leistung:
-5.98%
1M Leistung:
+17.19%
6M Leistung:
+141.91%
1J Leistung:
+149.70%
1-Tages-Spanne:
$12.43
$12.78
1-Wochen-Bereich:
$12.02
$13.28
52-Wochen-Spanne:
$4.35
$14.00
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
12.47 | 964.13M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 - Investing.com
Candel Therapeutics to Present at September Investor Conferences - The Manila Times
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock - MarketBeat
Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Hits New 1-Year HighHere's Why - MarketBeat
Candel Therapeutics CTO Seshu Tyagarajan Executes 7,000-Share Sale Under 10b5-1 Plan - Kalkine Media
Candel Therapeutics (NASDAQ: CADL) insider plans 7,000-share 10b5-1 sale - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Trading 6.4% Higher Following Analyst Upgrade - MarketBeat
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Weekly Recap: CAN-2409 BLA filing, 2027 U.S. launch target and Q2 widened loss, shares up - TradingView
Research Analysts Set Expectations for CADL Q3 Earnings - MarketBeat
CADL Q3 EPS Estimate Reduced by Brookline Capital Markets - MarketBeat
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
(CADL) Risk Channels and Responsive Allocation - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $23 - Moomoo
Stifel Nicolaus Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics (CADL) Receives a Hold from Bank of America Securities - The Globe and Mail
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss - MarketBeat
Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside - TradingView
BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 - Moomoo
Equities Analysts Offer Predictions for CADL FY2028 Earnings - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $25 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics grants stock options to new Chief Commercial Officer - scanx.trade
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - TradingView
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month HighHere's What Happened - MarketBeat
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Q2 EPS of $(0.52) misses estimates - scanx.trade
Candel Therapeutics Reports Q2 2026 Financials and Pipeline Progress in SEC Form 10-Q - Kalkine Media
Candel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):